Current Status of Uterine Leiomyosarcoma in the Tohoku Region: Results of the Tohoku Translational Center Development Network Survey

Hideki Tokunaga, Fumiaki Takahashi, Hiroki Yamamoto, Tsuyoshi Honda, Takafumi Watanabe, Tadahiro Shoji, Toru Sugiyama, Hidekazu Yamada, Tomoe Tando, Kosuke Yoshinaga, Satoko Kagabu, Takeo Otsuki, Shogo Kin, Yoshihito Yokoyama, Satoshige Wagatsuma, Kazuyo Sato, Hirokazu Sato, Takashi Oishi, Yuji Yoshida, Tadashi HayasakaToshihiko Matsui, Noriaki Imai, Hidekazu Nishigori, Hiroaki Shimokawa, Nobuo Yaegashi, Yoh Watanabe

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


Background: To prepare for a future clinical trial for improving the long-term prognosis of patients with uterine leiomyosarcoma (ULMS), we conducted a multi-institutional survey in the Tohoku region of Japan. Methods: We conducted a retrospective cohort study between 2011 and 2014 in member institutions of the Tohoku Translational Research Center Development Network. Results: A total of 53 patients with ULMS were registered in 31 institutions for the present survey. The median patient age was 56 years, 67.9% of the patients were postmenopausal, 88.7% had a performance status of 0 or 1, and only 6 patients (11.3%) showed preoperative evidence of malignancy. Although retroperitoneal lymphadenectomy was performed in only 26.4% of patients, 64.2% patients were identified as having FIGO stage 1 disease; 73.6% were eligible to undergo complete surgery. Among 36 patients who were treated with postoperative chemotherapy, 28 (77.8%) received docetaxel and gemcitabine combination therapy. The most frequent recurrence site was the lungs, and the median progression-free survival of all enrolled patients was 11.7 months. However, the median progression-free survival and the median overall survival in patients with stages III and IV disease were 3.4 and 11.4 months, respectively. Conclusion: Although ULMS was associated with a high rate of complete or optimal surgery, the long-term prognosis was poor. Effective postoperative therapy should be developed to improve the long-term prognosis of patients with ULMS.

Original languageEnglish
Pages (from-to)541-547
Number of pages7
JournalInternational Journal of Clinical Oncology
Issue number3
Publication statusPublished - 2017 Jun 1


  • Retrospective survey
  • Tohoku region
  • Uterine leiomyosarcoma

ASJC Scopus subject areas

  • Surgery
  • Hematology
  • Oncology


Dive into the research topics of 'Current Status of Uterine Leiomyosarcoma in the Tohoku Region: Results of the Tohoku Translational Center Development Network Survey'. Together they form a unique fingerprint.

Cite this